Biodesix (BDSX) Other Accumulated Expenses (2019 - 2026)

Biodesix has reported Other Accumulated Expenses for 8 years, with the latest figure at $927000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 57.69% year-over-year to $927000.0; the trailing twelve-month figure through Mar 2026 stood at $927000.0 (down 57.69% YoY), and the FY2025 full-year result was $992000.0, down 58.23% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $927000.0, down from $992000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.5 million in Q1 2024, with the low at $37000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.7 million across 5 years, with a median of $2.1 million in 2022.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 99.2% — and 2024, when it surged 2301.39%.
• Biodesix's Other Accumulated Expenses stood at $2.3 million in 2022, then gained by 24.06% to $2.9 million in 2023, then slipped by 17.31% to $2.4 million in 2024, then slumped by 58.23% to $992000.0 in 2025, then decreased by 6.55% to $927000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $927000.0 (Q1 2026), $992000.0 (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.